Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 30, 2008

View Archived Issues

New agents for treating HIV infection reported in recent patent literature

HIF prolyl hydroxylase inhibitors for anemia prepared and tested at GSK

Prevention of acute, chronic rejection of solid tissue allografts with regulatory T cells

Abbott presents fourth quarter 2007 results

Recent patents disclose novel neuropsychiatric agents

Asenapine demonstrates long-term efficacy in bipolar disorder

Generex receives Ukrainian approval for phase III clinical trial of Generex Oral-lyn

Phase II dose of E-7974 in 21-day schedule determined in solid tumor patients

No objective responses seen with tremelimumab in gastric, esophageal adenocarcinoma

Abbott and Eisai announce changes in the sales scheme for adalimumab in Japan

Arius completes pre-IND meeting with FDA for lead anticancer antibody

Arno Therapeutics completes license agreements for novel targeted cancer compounds

Nabilone improves pain, quality of life in fibromyalgia patients

Calibrant collaborates with Cleveland Clinic on brain cancer drug discovery

Derma enters phase II development for wound-healing product

FDA accepts sNDA for Fentora for management of breakthrough pain

Medivation plans pivotal confirmatory phase III Dimebon trial in AD

N30 Pharma initiates human studies with N30-201

Oncothyreon highlights corporate and clinical objectives for 2008

FDA accepts AZX-100 IND application in dermal/hypertrophic scarring

Acrux reports results for phase I fentanyl trial using metered-dose transdermal spray

FDA approves Emend for Injection as part of treatment for CINV

Neose discontinues NE-180 program

FDA approves IND for clinical phase II trial with uPA inhibitor WX-671

Serenex collaborates with NCI for small-molecule Hsp90 inhibitors in lung cancer

Peregrine opens enrollment in phase II bavituximab trial in advanced breast cancer

Acorda Therapeutics announces successful QT study of Fampridine-SR

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...